ARVN pipeline update: four programs advance; data due within 15 months
ARVN said four programs are advancing as it shifts to a robust clinical pipeline. ARV-393 and ARV-102 are progressing in hematology and neurodegeneration, while SBMA and HPK1 target rare disease and immuno-oncology; key data expected within 15 months.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.